- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 ehxm 的帖子
Safety and Efficacy of Stem Cell Transplantation for Treatment of Liver Cirrhosis
This study is currently recruiting participants.
Verified October 2012 by General Hospital of Chinese Armed Police Forces
Sponsor:
General Hospital of Chinese Armed Police Forces
Collaborators:
Xinjiang Armed Police Corps Hospital
Taian Hospital of Traditional Chinese Medicine
Information provided by (Responsible Party):
General Hospital of Chinese Armed Police Forces
ClinicalTrials.gov Identifier:
NCT01491165
First received: December 8, 2011
Last updated: October 25, 2012
Last verified: October 2012
History of Changes
Purpose
Mainstream of current treatment of liver cirrhosis is liver transplantation, but there are high cost, risk and immune rejection and other issues. Umbilical cord mesenchyma stem cell with self-and directed differentiation capacity can effectively rescue experimental liver failure and contribute to liver regeneration, which suggests the feasibility of stem cell transplantation therapy. In this study, the safety and efficacy of umbilical cord mesenchyma stem cell transplantation through interventional procedures in patients liver cirrhosis will be evaluated.
Locations
China
Yihua An Recruiting
Beijing, China
Contact: Yihua An, doctor 0086-10-88276848 [email protected]
干细胞移植治疗肝硬化的疗效和安全性
这项研究目前正在招募参与者。
已验证的2012年10月由中国人民武装警察部队总医院
承办单位:
中国人民武装警察部队总医院
合作者:
武警新疆总队医院
泰安医院中国传统医药
(责任方)提供的信息:
中国人民武装警察部队总医院
ClinicalTrials.gov标识符:
NCT01491165
第一次收到2011年12月8日日
最后更新:2012年10月25日
最后验证:2012年10月
目的
目前主流治疗肝硬化是肝移植,但有很高的成本,风险和免疫排斥反应等问题。脐带间充质干细胞的自我定向分化的能力可以有效地挽救实验性肝衰竭,促进肝再生,这表明干细胞移植治疗的可行性。在这项研究中,通过介入手术的患者肝硬化脐带间充质干细胞移植的安全性和有效性进行评估。
地点
中国
怡华
安 招聘
北京,中国
联系人:怡华安,医生0086-10-88276848 [email protected]的
|
|